Christina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now directly owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36.

Blueprint Medicines Stock Performance

BPMC opened at $89.73 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The firm has a market cap of $5.73 billion, a PE ratio of -83.08 and a beta of 0.58. The business has a fifty day simple moving average of $98.55 and a 200-day simple moving average of $93.92. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BPMC has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Wolfe Research began coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating for the company. Finally, Piper Sandler lifted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $124.95.

Institutional Investors Weigh In On Blueprint Medicines

Large investors have recently made changes to their positions in the company. Quarry LP purchased a new position in Blueprint Medicines during the 3rd quarter worth approximately $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $51,000. Headlands Technologies LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at $65,000. Thematics Asset Management acquired a new position in Blueprint Medicines during the fourth quarter valued at $72,000. Finally, Covestor Ltd raised its position in Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 375 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.